Use of progestagens to preserve pregnancy: modern approaches

Literature review

Authors

DOI:

https://doi.org/10.18370/2309-4117.2023.69.36-40

Keywords:

miscarriage, recurrent miscarriage, threatened miscarriage, vaginal bleeding, luteal phase support, progesterone support

Abstract

Review objectives: to summarize current and clinical data on the role of progesterone support in women at risk of miscarriage and premature pregnancy according to the standards of evidence-based medicine. Control of plasma progesterone levels is a fundamental tool for managing the effectiveness of assisted reproductive technologies. The association of a low level of serum progesterone with lower rates of current pregnancy and live birth in cycles of assisted reproductive technologies was revealed. Patients with low serum progesterone on the day of embryo transfer need individualized support of the luteal phase, which involves adding additional doses of progesterone to standard regimens.

Vaginal micronized progesterone is currently believed to be the only progestogen that increases the likelihood of a live birth in women with bleeding in early pregnancy which has one or more miscarriages.

Vaginal progesterone can be considered for patients with a high risk of miscarriage in the following modes: with vaginal bleeding and a history of one or more miscarriages (threatened miscarriage) – 400 mg twice a day, starting with the detection of vaginal bleeding up to 16 full weeks of pregnancy; with a history of three or more pregnancy losses of unknown etiology (habitual miscarriage) – asymptomatic patients — 200 mg twice a day up to 12 full weeks of pregnancy; patients with vaginal bleeding – 400 mg 2 times a day up to 16 weeks of pregnancy. Currently, there is no evidence of the effectiveness other forms of progesterone and other doses.

Conclusions. Vaginal micronized progesterone demonstrated: high efficiency as a standard of luteal phase support; increasing the chance of a live birth in women with a double risk factor for miscarriage (vaginal bleeding in the 1st trimester and ≥1 previous miscarriage); the absence of safety problems for the fetus and the health of newborns when used in the early and late stages of pregnancy.

Author Biographies

S.I. Zhuk, P.L. Shupyk National Healthcare University of Ukraine, Kyiv

MD, professor, head of Obstetrics, Gynecology and Fetal Medicine Department

I.V. Us, Shupyk National Healthcare University of Ukraine; «Perinatal Center of Kyiv», Kyiv

PhD, assistant professor, Obstetrics, Gynecology and Fetal Medicine Department;
obstetrician-gynecologist, hematologist

References

  1. Gaggiotti-Marre, S. et al. Low progesterone levels on the day before natural cycle frozen embryo transfer are negatively associated with live birth rates, Human Reproduction 7 (2020): 1623–29. https://doi.org/10.1093/humrep/deaa092
  2. Schliep, K.C., Mumford, S.L., Hammoud, A.O., et al. “Luteal phase deficiency in regularly menstruating women: prevalence and overlap in identification based on clinical and biochemical diagnostic criteria.” J Clin Endocrinol Metab. Jun 6 (2014): E1007–14.
  3. Steven L. Young, Ricardo F. Savaris, Bruce A. Lessey, et al. “Effect of randomized serum progesterone concentration on secretory endometrial histologic development and gene expression,” Human Reproduction, 32, 9 (2017): 1903–14. https://doi.org/10.1093/humrep/dex252
  4. Bulletti, C., Bulletti, F.M., Sciorio, R., Guido, M. “Progesterone: The Key Factor of the Beginning of Life.” Int. J. Mol. Sci. 23 (2022): 14138.
  5. van der Linden, M., Buckingham, K., Farquhar, C., et al. “Luteal phase support for assisted reproduction cycles.” Cochrane Database Syst Rev. Jul 7 (2015): CD009154.
  6. Ranisavljevic, N., Huberlant, S., Montagut, M., et al. “Low Luteal Serum Progesterone Levels Are Associated with Lower Ongoing Pregnancy and Live Birth Rates in ART: Systematic Review and Meta-Analyses.” Front Endocrinol (Lausanne). Jun 10. 13 (2022). DOI: 10.3389/fendo.2022.892753.
  7. Labarta, E., Mariani, G., Rodriguez-Varela, C., Bosch, E. “Individualized luteal phase support normalizes live birth rate in women with low progesterone levels on the day of embryo transfer in artificial endometrial preparation cycles.” Fertil Steril. Jan 117.1 (2022): 96–103.
  8. Shoham, G., Leong, M., Weissman, A. “A 10-year follow-up on the practice of luteal phase support using worldwide web-based surveys.” Reprod Biol Endocrinol. Jan 26; 19.1 (2021): 15. DOI: 10.1186/s12958-021-00696-2.
  9. Nadarajah, R., Rajesh, H., Wong, K.Y., “Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques.” Singapore Med J. Jun 58 (2017): 294–7. DOI: 10.11622/smedj.2016080.
  10. Henry, А., Santulli, P., Bourdon, M., Treluyer, J.M., et al. “Birth defects reporting and the use of oral dydrogesterone in assisted reproductive technology: a global pharmacovigilance study.” Human Reproduction. 38. 1, June (2023). DOI: 10.1093/humrep/dead093.177.
  11. Bosch, E., Broer, S., Griesinger, G., et al. “ESHRE guideline: ovarian stimulation for IVF/ICSI.” May 1.2 (2020). DOI: 10.1093/hropen/hoaa009.
  12. Dhorepatil, B., Yang, D.Z., Chen, Z.J., “Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial.” Hum Reprod. Dec 33 (2018): 2212–21. DOI: 10.1093/humrep/dey306.
  13. Tournaye, H., Sukhikh, G.T., Kahler, E., Griesinger, G. “A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization.” Hum Reprod. May 1. 32.5 (2017): 1019–27. DOI: 10.1093/humrep/dex023.
  14. Griesinger, G., Blockeel, C., Kahler, E., et al. “Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis.” PLoS One. Nov 4, 15 (2020). DOI: 10.1371/journal.pone.0241044.
  15. Balasch, J., Vanrell, J.A., Rivera, F., Gonzalez-Merlo, J. The effect of postovulatory administration of dehydrogesterone on plasma progesterone levels. Fertil Steril. Jul 34.1 (1980): 21–3. DOI: 10.1016/s0015-0282(16)44832-6.
  16. Ghasemzadeh , A., Dopour Faliz, M., Farzadi, L., “Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: A randomized controlled trial.” Int J Reprod Biomed. Jan 18 (2020): 41–46. DOI: 10.18502/ijrm.v18i1.6197.
  17. Zhu, X., Ye, H., Fu, Y. “Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a «freeze all» strategy: a randomized controlled dosefinding study of 100 mg versus 200 mg.” Fertil Steril. Feb 107.2 (2017): 379–386.e4. DOI: 10.1016/j.fertnstert.2016.10.030.
  18. Casarramona, G., Lalmahomed, T., Lemmen, C., The efficacy and safety of luteal phase support with progesterone following ovarian stimulation and intrauterine insemination: A systematic review and meta-analysis. Front Endocrinol (Lausanne). Sep 2, 13 (2022). DOI: 10.3389/fendo.2022.960393.
  19. Mrozikiewicz, A.E., Ożarowski, M., Jędrzejczak, P. “Biomolecular Markers of Recurrent Implantation Failure–A Review.” J. Mol. Sci. 22 (2021). DOI: 10.3390/ijms221810082.
  20. Mesiano, S. The Role of Progesterone in Pregnancy. In F. Petraglia, M. Di Tommaso, & F. Mecacci (Eds.), Hormones and Pregnancy: Basic Science and Clinical Implications (2022): 50–60. Cambridge: Cambridge University Press. DOI: 10.1017/9781009030830.006. Available from: [https://www.cambridge.org/core/books/ abs/hormones-and-pregnancy/role-of-progesterone-inpregnancy/ EC24EC27222B55224A017B67E9CEEC7E], last accessed 20.10.2023.
  21. Raghupathy, R., Szekeres-Bartho, J. “Progesterone: A Unique Hormone with Immunomodulatory Roles in Pregnancy.” Int. J. Mol. Sci. 23 (2022). DOI: 10.3390/ijms23031333.
  22. Di Renzo, G.C., Giardina, I., Clerici, G., et al. “The role of progesterone in maternal and fetal medicine.” Gynecol Endocrinol. Nov; 28 (2012): 925–32. DOI: 10.3109/09513590.2012.730576.
  23. Pandian, R.U. “Dydrogesterone in threatened miscarriage: a Malaysian experience.” Maturitas. Dec, 65. 1 (2009): S47–50. DOI: 10.1016/j.maturitas.2009.11.016.
  24. Siew, J.Y.S., Allen, J.C., Hui, C.Y.Y., et al. “The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage.” Eur J Obstet Gynecol Reprod Biol. Sep 228 (2018): 319–24. DOI: 10.1016/j.ejogrb.2018.07.028.
  25. Coomarasamy, A., Devall, A.J., Cheed, V., et al. “Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy.” N Engl J Med. May 9; 380.19 (2019): 1815–24. DOI: 10.1056/NEJMoa1813730.
  26. Chan, D.M.K., Cheung, K.W., Ko, J.K.Y., Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double-blind controlled trial. Hum Reprod. Feb 18; 36.3 (2021): 587–95. DOI: 10.1093/humrep/deaa327.
  27. Coomarasamy, A., Williams, H., Truchanowicz, E., et al. “PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages — a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation.” Health Technol Assess. May 20.41 (2016): 1–92. DOI: 10.3310/hta20410.
  28. Hasan, R., Baird, D.D., Herring, A.H., et al. “Association between first-trimester vaginal bleeding and miscarriage.” Obstet Gynecol. Oct 114. 4 (2009): 860–67. DOI: 10.1097/AOG.0b013e3181b79796.
  29. Deval, A.J., Coomarasamy, A. “Sporadic pregnancy loss and recurrent miscarriage.” Best Practice & Research Clinical Obstetrics and Gynaecology 69 (2020): 30–9.
  30. van Oppenraaij, R.H., Jauniaux, E., Christiansen, O.B., “ESHRE Special Interest Group for Early Pregnancy (SIGEP). Predicting adverse obstetric outcome after early pregnancy events and complications: a review.” Hum Reprod Update. Jul- Aug 15.4 (2009): 409–21.
  31. Ku, C.W., Allen, J.C., Malhotra, R., et al. “How can we better predict the risk of spontaneous miscarriage among women experiencing threatened miscarriage.” Gynecol. Endocrinol 31 (2015):647–51.
  32. Lek S.M., Ku C.W., Allen J.C., “Validation of serum progesterone.” BMC Pregnancy Childbirth 17 (2017):78.
  33. Coomarasamy, A., Gallos, I.D., Papadopoulou, A., et al. “Sporadic miscarriage: evidence to provide effective care.” Lancet. May 1; 397 (2021): 1668–74.
  34. Magnus, M.C., Wilcox, A.J., Morken, N., et al. “Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study” BMJ 364 (2019). DOI:10.1136/bmj.l869.
  35. Devall, A.J., Papadopoulou, A., Podesek, M., et al. “Progestogens for preventing miscarriage: a network meta-analysis.” Cochrane Database Syst Rev. Apr 19; 4 (2021):CD013792.
  36. Coomarasamy, A., Devall, A.J., Brosens, J.J., et al. “Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence.” Am J Obstet Gynecol 19 (2020): 167e76.
  37. National Institute for Health and Care Excellence updated the guideline ‘Ectopic pregnancy and miscarriage: diagnosis and initial management NG126)’. Last update 24 November 2021. Available from: [https://rh.ua/statti/profilaktika-vtrativagitnosti- poyednannya-likuvannya-progestagenami-tapsixologichnoyi-pidtrimki/], last accessed 20.10.2023.
  38. Bender, Atik R., Christiansen, O.B., Elson, J., et al “ESHRE guideline: recurrent pregnancy loss: an update in 2022”. Hum Reprod Open. Mar 2; 1 (20231): hoad002.
  39. AWMF Leitlinienregister. S2k Langfassung der Leitlinie Diagnostik und Therapie von Frauen mit wiederholten Spontanaborten, August 2022. Version 6.1. Available from: [https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1895-9940?articleLanguage=de], last accessed 20.10.2023.
  40. Quenby, S. et al. “Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss.” Lancet. May 1; 397 (2021): 1658–67.
  41. Chester, M.R., Tirlapur, A., Jayaprakasan, K. “Current management of recurrent pregnancy loss.” The Obstetric & Gynaecologis (2022). DOI: 10.1111/tog.12832.
  42. Coomarasamy, A., Dhillon-Smith, R.K. et al. “Recurrent miscarriage: evidence to accelerate action.” Lancet. May 1; 397 (2021): 1675–82.
  43. Murphy, C.C., Cirillo, P.M., Krigbaum, N.Y., Cohn, B.A. “In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring.” Am J Obstet Gynecol. Jan 226 (2022): 132.e1–14. DOI: 10.1016/j.ajog.2021.10.035
  44. Care, A., Nevitt, S.J., Medley, N., et al. “Interventions to prevent spontaneous preterm birth in women with singleton pregnancy who are at high risk: systematic review and network meta- analysis” BMJ 376 (2022): e064547.

Downloads

Published

2023-09-29

How to Cite

Zhuk, S., & Us, I. (2023). Use of progestagens to preserve pregnancy: modern approaches: Literature review. REPRODUCTIVE ENDOCRINOLOGY, (69), 36–40. https://doi.org/10.18370/2309-4117.2023.69.36-40

Issue

No. 69 (2023)

Section

Pregnancy and childbirth

License

Copyright (c) 2023 С.І. Жук, І.В. Ус

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.